Eggs of Xenopus laevis undergo a postfertilization cortical rotation that specifies the position of the dorso-ventral axis and activates a transplantable dorsal-determining activity in dorsal blastomeres by the 32-cell stage. There have heretofore been no reported dorso-ventral asymmetries in endogenous signaling proteins that may be involved in this dorsal-determining activity during early cleavage stages. We focused on β-catenin as a candidate for an asymmetrically localized dorsal-determining factor since it is both necessary and sufficient for dorsal axis formation. We report that β-catenin displays greater cytoplasmic accumulation on the future dorsal side of the Xenopus embryo by the two-cell stage. This asymmetry persists and increases through early cleavage stages, with β-catenin accumulating in dorsal but not ventral nuclei by the 16- to 32cell stages. We then investigated which potential signaling factors and pathways are capable of modulating the steady-state levels of endogenous β-catenin. Steadystate levels and nuclear accumulation of β-catenin increased in response to ectopic Xenopus Wnt-8 (Xwnt-8) and to the inhibition of glycogen synthase kinase-3, whereas neither Xwnt-5A, BVg1, nor noggin increased β-catenin levels before the mid-blastula stage. As greater levels and nuclear accumulation of β-catenin on the future dorsal side of the embryo correlate with the induction of specific dorsal genes, our data suggest that early asymmetries in β-catenin presage and may specify dorso-ventral differences in gene expression and cell fate. Our data further support the hypothesis that these dorso-ventral differences in β-catenin arise in response to the postfertilization activation of a signaling pathway that involves Xenopus glycogen synthase kinase-3.
Skip Nav Destination
Article navigation
10 March 1997
Article|
March 10 1997
Establishment of the Dorso-ventral Axis in Xenopus Embryos Is Presaged by Early Asymmetries in β-Catenin That Are Modulated by the Wnt Signaling Pathway
Carolyn A. Larabell,
Carolyn A. Larabell
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Search for other works by this author on:
Monica Torres,
Monica Torres
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Search for other works by this author on:
Brian A. Rowning,
Brian A. Rowning
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Search for other works by this author on:
Cynthia Yost,
Cynthia Yost
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Search for other works by this author on:
Jeffrey R. Miller,
Jeffrey R. Miller
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Search for other works by this author on:
Mike Wu,
Mike Wu
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Search for other works by this author on:
David Kimelman,
David Kimelman
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Search for other works by this author on:
Randall T. Moon
Randall T. Moon
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Search for other works by this author on:
Carolyn A. Larabell
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Monica Torres
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Brian A. Rowning
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Cynthia Yost
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Jeffrey R. Miller
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Mike Wu
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
David Kimelman
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Randall T. Moon
*Howard Hughes Medical Institute and Department of Pharmacology, ‡Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195; and §Lawrence Berkeley National Laboratory, ‖Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
Carolyn Larabell and Monica Torres contributed equally to this work.
M. Torres, J. Miller, and R. Moon were supported by the Howard Hughes Medical Institute, and B. Rowning (HD27525 and HD 29360 to R.T. Moon), C. Yost (GM 07270), and D. Kimelman (HD27262) were supported by Public Health Service Awards from the National Institutes of Health. C. Larabell was supported by the Office of Health and Environmental Research, U.S. Department of Energy.
Note Added in Proof. β-Catenin was translated in vitro and labeled with [35S]methionine (as in Yost et al., 1996), then comparable amounts were injected into either dorsal or ventral blastomeres of four-cell embryos. Monitoring the injected β-catenin by SDS-PAGE and autoradiography demonstrates that it is more stable on the dorsal side of the embryo, as predicted by our experiments presented here and in Yost et al. (1996).
Address all correspondence to Randall T. Moon, Howard Hughes Medical Institute, Campus Box 357370, Room K536C Health Sciences Building, University of Washington School of Medicine, Seattle, WA 98195. Tel.: (206) 543-1722. Fax: (206) [email protected]
Received:
September 06 1996
Revision Received:
November 05 1996
Online ISSN: 1540-8140
Print ISSN: 0021-9525
1997
J Cell Biol (1997) 136 (5): 1123–1136.
Article history
Received:
September 06 1996
Revision Received:
November 05 1996
Citation
Carolyn A. Larabell, Monica Torres, Brian A. Rowning, Cynthia Yost, Jeffrey R. Miller, Mike Wu, David Kimelman, Randall T. Moon; Establishment of the Dorso-ventral Axis in Xenopus Embryos Is Presaged by Early Asymmetries in β-Catenin That Are Modulated by the Wnt Signaling Pathway. J Cell Biol 10 March 1997; 136 (5): 1123–1136. doi: https://doi.org/10.1083/jcb.136.5.1123
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
Advertisement
